Canopy Growth Reports Improved Financials Despite Stock Struggles
In its fiscal 2027 first-quarter report for the period ending June 30, 2026, Canopy Growth reported a 13% year-over-year increase in net revenue to $81.2 million CAD ($58.6 million). The company also noted improved gross margins and significant reductions in both net losses (down 68%) and adjusted EBITDA losses (down 59%). Despite these positive developments, the stock remains below $1 per share. The article highlights two key challenges affecting investor sentiment: slow progress on U.S. federal marijuana legalization and ongoing equity dilution due to Canopy's reliance on at-the-market offerings. Although medical cannabis was rescheduled from Schedule I to III in April 2026, recreational use remains unaddressed, limiting the company’s potential expansion into the lucrative U.S. market. Canopy has increased its share count by nearly 76% over the past year and could raise an additional $200 million through a new ATM program, which risks further diluting shareholders.
Tickers: $CGC